Levamisole and Cell-Mediated Immunity
- 16 August 1973
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 289 (7), 375-376
- https://doi.org/10.1056/nejm197308162890715
Abstract
Current widespread interest in the contribution of host immunity to resistance to tumor growth is based on evidence from a variety of animal and human studies.1 Host resistance is mediated by sensitized lymphocytes, and in some cases, in vitro studies have indicated that serum factors may abrogate this protective function.2 In addition to the effect of cells sensitized to tumor antigens, protection may also result from nonspecific stimulation of the immune system such as that caused by BCG.Previous studies have shown that patients with cancer who have absent delayed-type hypersensitivity have a poorer prognosis than those with positive skin . . .Keywords
This publication has 6 references indexed in Scilit:
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973
- Management of Adult Acute Myelogenous LeukaemiaBMJ, 1973
- Possibilities and Problems of Immunologic Intervention in CancerNew England Journal of Medicine, 1972
- Immunotherapy of Cancer: Regression of Tumors after Intralesional Injection of Living Mycobacterium bovisScience, 1971
- Cell-Mediated Immunity to Human Tumor AntigensPublished by Elsevier ,1971
- Impaired immunologic reactivity and recurrence following cancer surgeryCancer, 1970